Overcoming market access barriers to high-value drugs
How can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US?
Pharma faces unprecedented demands from payers, patients, HTAs and KOLs to prove value and utility for high-cost therapies in key conditions such as Cancer, Multiple Sclerosis, HIV and Rheumatoid Arthritis. Get it wrong, and you won’t achieve formulary listing, reimbursement or an optimum price. Further, there is a trend in key markets to empower local decision making, radically increasing the number of stakeholder touch points. In a time of budget constraint, how can companies up their game to meet the growing challenges?
This report is available for immediate download after purchase -- buy your report now.
Report Overview
In Overcoming Market Access Barriers to High-value Drugs senior industry experts from leading pharma companies address 7 key barriers and propose actionable solutions to ensure market access success. Buy the report now.
Report Features
- Unique insights from US and EU experts from companies such as Pfizer, Merck, UCB and Celgene
- Case Study: Differentiating CIMZIA from other anti-TNF products to demonstrate value for patients beyond tender offers
- Table: Impact of barriers on prescription and market share of immunology brands
- Table: Impact of barriers on prescription and market share of oncology brands
- Charts showing the overall impact of market access barriers on prescriptions for Melanoma, Multiple Melanoma. Non-Small Cell Lung Cancer and Renal Cell Carcinoma
- Charts showing the overall impact of market access barriers on prescriptions for Psoriasis, HIV, Multiple Sclerosis, and Rheumatoid Arthritis
- The challenges for overcoming market access barriers in oncology and immunology
- Recommendations for overcoming market access barriers
Key Benefits
- Understand how the biosimilar market has grown in 2016 and what are the stand out developments
- Investigate national trends driving adoption, pricing and reimbursement of biosimilars.
- Examine how biosimilar cost savings are being reinvested in health and the positive impact this is having on payer perceptions
- Gain insight into the role of patient groups whose voice is becoming increasingly heard in biosimilars discussions
- Assess the current climate for price discounting and why a uniform price reduction is unlikely among EU member states
- Review the ongoing arguments for switching from originator to biosimilar products and learn how they differ at the national level
- Create communication strategies that challenge misinformation and instil confidence in clinicians and patients
Report available for immediate download -- place your order today
Key Questions Answered By This Report
- Value: All stakeholders want value, but what does value mean to each of them?
- US/EU5: How do market access barriers differ between the US and EU5?
- Cost: Brands being too expensive is the overriding market access barrier. What solutions do experts propose?
- Formulary: Not achieving formulary position is a major obstacle impacting prescribing levels and market position – what do you need to do to overcome this barrier?
- Localism: What practical actions can you take to understand and meet local stakeholder needs?
- Staffing: What capabilities will front line staff need in the future and what are the implications for training and recruitment?
- Beyond the Pill: What role can value added services play in gaining market access?
- Resourcing: Future market access teams will demand greater resources; how can senior management plan to meet this demand?
Report available for immediate download -- place your order now
Expert Views
- Ildar Akhmetov, Consultant, Global Market Access & Pricing (I&I) at Pfizer Chetak Buaria, Global Head of Commercial Excellence, Merck KGaA
- Lee Gervitz, Head of Patient Value Mission for Rheumatoid Arthritis & Women of Childbearing Age, UCB
- Alex Grosvenor, Senior Principal, Global Pricing & Market Access at Precision for Value
- Michael Kleinrock, Research Director at QuintilesIMS in the US
- Mahendra Kumar Rai, Delivery Head - Market Access (HEOR, PRMA, RWE), Tata Consultancy Services
- Nicola Redfern, Previously Director of Oncology Market Access at Baxalta and Director of Market Access and Corporate Affairs at Celgene
- Chris Martin, Director at InTeg Access Limited
- Andrea Passalacqua, Executive Director, Pricing and Market Access, Celgene
- Anonymous: Global Market Access Manager at a leading biotechnology company
4 Key Quotes
“The value story for payers and policymakers for your product [is important]. Often, companies have the challenge of not having local data available. They must determine how to work with local stakeholders to build a credible value story for their medicine.”
Chetak Buaria,
Global Head of Commercial Excellence, Merck KGaA
Anonymous,
Global Market Access Manager at a leading biotechnology company
“To address the patient preference aspect of market access barriers, you must develop strong relationships with your patient advocacy groups so that the patients have accurate information available to them about your product from independent sources. There are highly active patient organisations involved in particular cancer types, where patients are very aware of their disease and its implications. You also need to look at what endpoints are important to patients so that they will get behind you and support, argue for, and champion the access to your product.”
Nicola Redfern,
Previously Director of Oncology Market Access at Baxalta and
Director of Market Access and Corporate Affairs at Celgene
“You want to keep on building on the data and the value that you offer over the course of the product lifecycle. What you need to do is determine how you can work with select KOLs to build incremental data, since not everything will be available when you launch a product.”
Chetak Buaria,
Global Head of Commercial Excellence, Merck KGaA
Critical insights from these and many other respected experts available for immediate download —place your order here
Who Would Benefit from This Report?
- Market access teams charged with meeting the specific information and data needs of physicians, payers, HTAs and patients
- HEOR teams building evidence of value for high-cost therapies
- Commercial teams needing to understand market access issues impacting prescribing and availability
- MSL teams needing to demonstrate product safety and efficacy with KOLs and patient groups
- Post-marketing surveillance teams analysing long-term real-world data to support ongoing use of brands
- Teams monitoring competitor activity and identifying opportunity
- Senior management and resource planners needing to ensure investment in the market access function and personnel
Report available for immediate download — place your order now
Content Highlights
- Executive summary
- Research objectives and methodology
- The evolving market access landscape
- Evolving pricing and reimbursement rules
- Changing customer structure
- New appraisal/assessment methods
- Understanding specific market access barriers
- The cancer and immunology market access landscape
- The immunology market access landscape – US and EU5 trends
- The top three market access barriers in immunology
- Top barrier 1: The medicine is too expensive
- Top barrier 2: The medicine is not available on formulary
- Top barrier 3: The medicine is only for certain types of patients
- The cancer market access landscape - US and EU5 trends
- The top three barriers for oncology medicines
- Top barrier 1: The brand is too expensive
- Top barrier 2: The medicine is not reimbursable
- Top barrier 3: Brand is recommended for certain types of patients
- Challenges to overcoming market access barriers
- Restrictive pricing policies and reimbursement restrictions
- Meeting payer needs
- Complexity of payer environment
- The lack of internal alignment with organisations
- Recommendations for overcoming market access barriers
- Enhance market access skills and capabilities
- Improve data collection to enhance the value story
- Intense engagement with patients
- Treating stakeholders as partners
- Placing greater priority in local access efforts
- Key takeaways
- Market authorisation and regulatory approval are not assurances of patient access
- Market access barriers can be used to a brand’s advantage
- Build relationships that are stakeholder-centric
- Continuing to update and communicate a brand’s value story
- Skills training for market access teams
- Innovative payment and access schemes will be the future of patient access in oncology and immunology
This critical intelligence is available for immediate download — order your copy now
Need more information? Contact a consultant for an executive summary and sample pages from the report.
Overcoming market access barriers to high-value drugs
How can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US?
Pharma faces unprecedented demands from payers, patients, HTAs and KOLs to prove value and utility for high-cost therapies in key conditions such as Cancer, Multiple Sclerosis, HIV and Rheumatoid Arthritis. Get it wrong, and you won’t achieve formulary listing, reimbursement or an optimum price. Further, there is a trend in key markets to empower local decision making, radically increasing the number of stakeholder touch points. In a time of budget constraint, how can companies up their game to meet the growing challenges?
This report is available for immediate download after purchase -- buy your report now.
Report Overview
In Overcoming Market Access Barriers to High-value Drugs senior industry experts from leading pharma companies address 7 key barriers and propose actionable solutions to ensure market access success. Buy the report now.
Report Features
- Unique insights from US and EU experts from companies such as Pfizer, Merck, UCB and Celgene
- Case Study: Differentiating CIMZIA from other anti-TNF products to demonstrate value for patients beyond tender offers
- Table: Impact of barriers on prescription and market share of immunology brands
- Table: Impact of barriers on prescription and market share of oncology brands
- Charts showing the overall impact of market access barriers on prescriptions for Melanoma, Multiple Melanoma. Non-Small Cell Lung Cancer and Renal Cell Carcinoma
- Charts showing the overall impact of market access barriers on prescriptions for Psoriasis, HIV, Multiple Sclerosis, and Rheumatoid Arthritis
- The challenges for overcoming market access barriers in oncology and immunology
- Recommendations for overcoming market access barriers
Key Benefits
- Understand how the biosimilar market has grown in 2016 and what are the stand out developments
- Investigate national trends driving adoption, pricing and reimbursement of biosimilars.
- Examine how biosimilar cost savings are being reinvested in health and the positive impact this is having on payer perceptions
- Gain insight into the role of patient groups whose voice is becoming increasingly heard in biosimilars discussions
- Assess the current climate for price discounting and why a uniform price reduction is unlikely among EU member states
- Review the ongoing arguments for switching from originator to biosimilar products and learn how they differ at the national level
- Create communication strategies that challenge misinformation and instil confidence in clinicians and patients
Report available for immediate download -- place your order today
Key Questions Answered By This Report
- Value: All stakeholders want value, but what does value mean to each of them?
- US/EU5: How do market access barriers differ between the US and EU5?
- Cost: Brands being too expensive is the overriding market access barrier. What solutions do experts propose?
- Formulary: Not achieving formulary position is a major obstacle impacting prescribing levels and market position – what do you need to do to overcome this barrier?
- Localism: What practical actions can you take to understand and meet local stakeholder needs?
- Staffing: What capabilities will front line staff need in the future and what are the implications for training and recruitment?
- Beyond the Pill: What role can value added services play in gaining market access?
- Resourcing: Future market access teams will demand greater resources; how can senior management plan to meet this demand?
Report available for immediate download -- place your order now
Expert Views
Each industry expert has been carefully selected for their practical experience and detailed knowledge of current US/EU5 market access challenges.
- Ildar Akhmetov, Consultant, Global Market Access & Pricing (I&I) at Pfizer Chetak Buaria, Global Head of Commercial Excellence, Merck KGaA
- Lee Gervitz, Head of Patient Value Mission for Rheumatoid Arthritis & Women of Childbearing Age, UCB
- Alex Grosvenor, Senior Principal, Global Pricing & Market Access at Precision for Value
- Michael Kleinrock, Research Director at QuintilesIMS in the US
- Mahendra Kumar Rai, Delivery Head - Market Access (HEOR, PRMA, RWE), Tata Consultancy Services
- Nicola Redfern, Previously Director of Oncology Market Access at Baxalta and Director of Market Access and Corporate Affairs at Celgene
- Chris Martin, Director at InTeg Access Limited
- Andrea Passalacqua, Executive Director, Pricing and Market Access, Celgene
- Anonymous: Global Market Access Manager at a leading biotechnology company
4 Key Quotes
“The value story for payers and policymakers for your product [is important]. Often, companies have the challenge of not having local data available. They must determine how to work with local stakeholders to build a credible value story for their medicine.”
Chetak Buaria,
Global Head of Commercial Excellence, Merck KGaA
Anonymous,
Global Market Access Manager at a leading biotechnology company
“To address the patient preference aspect of market access barriers, you must develop strong relationships with your patient advocacy groups so that the patients have accurate information available to them about your product from independent sources. There are highly active patient organisations involved in particular cancer types, where patients are very aware of their disease and its implications. You also need to look at what endpoints are important to patients so that they will get behind you and support, argue for, and champion the access to your product.”
Nicola Redfern,
Previously Director of Oncology Market Access at Baxalta and
Director of Market Access and Corporate Affairs at Celgene
“You want to keep on building on the data and the value that you offer over the course of the product lifecycle. What you need to do is determine how you can work with select KOLs to build incremental data, since not everything will be available when you launch a product.”
Chetak Buaria,
Global Head of Commercial Excellence, Merck KGaA
Critical insights from these and many other respected experts available for immediate download —place your order here
Who Would Benefit from This Report?
- Market access teams charged with meeting the specific information and data needs of physicians, payers, HTAs and patients
- HEOR teams building evidence of value for high-cost therapies
- Commercial teams needing to understand market access issues impacting prescribing and availability
- MSL teams needing to demonstrate product safety and efficacy with KOLs and patient groups
- Post-marketing surveillance teams analysing long-term real-world data to support ongoing use of brands
- Teams monitoring competitor activity and identifying opportunity
- Senior management and resource planners needing to ensure investment in the market access function and personnel
Report available for immediate download — place your order now
Content Highlights
- Executive summary
- Research objectives and methodology
- The evolving market access landscape
- Evolving pricing and reimbursement rules
- Changing customer structure
- New appraisal/assessment methods
- Understanding specific market access barriers
- The cancer and immunology market access landscape
- The immunology market access landscape – US and EU5 trends
- The top three market access barriers in immunology
- Top barrier 1: The medicine is too expensive
- Top barrier 2: The medicine is not available on formulary
- Top barrier 3: The medicine is only for certain types of patients
- The cancer market access landscape - US and EU5 trends
- The top three barriers for oncology medicines
- Top barrier 1: The brand is too expensive
- Top barrier 2: The medicine is not reimbursable
- Top barrier 3: Brand is recommended for certain types of patients
- Challenges to overcoming market access barriers
- Restrictive pricing policies and reimbursement restrictions
- Meeting payer needs
- Complexity of payer environment
- The lack of internal alignment with organisations
- Recommendations for overcoming market access barriers
- Enhance market access skills and capabilities
- Improve data collection to enhance the value story
- Intense engagement with patients
- Treating stakeholders as partners
- Placing greater priority in local access efforts
- Key takeaways
- Market authorisation and regulatory approval are not assurances of patient access
- Market access barriers can be used to a brand’s advantage
- Build relationships that are stakeholder-centric
- Continuing to update and communicate a brand’s value story
- Skills training for market access teams
- Innovative payment and access schemes will be the future of patient access in oncology and immunology
This critical intelligence is available for immediate download — order your copy now
Need more information? Contact a consultant for an executive summary and sample pages from the report.
